Crely develops multimodal monitoring and clinical-intelligence technology to help care teams see postoperative complications sooner — across the ICU, ward, and recovery at home.
Deterioration doesn't wait for the next observation. Our mission is to close the gap between intermittent checks — so care teams see change while there is still time to act.
We build continuous, interpretable monitoring for the postoperative period: technology that earns clinical trust by explaining the physiology it reads, showing its evidence honestly, and fitting the way care teams already work. Credible, reliable, and early — in that order.
The same commitments guide every decision — from which problems we take on to how we present our evidence.
We begin from complications that matter to patients and teams — not from what is easiest to measure.
Continuous signals reveal change that intermittent checks miss.
Several modalities confirm change more reliably than any single measure.
Outputs are explainable and fit the clinical workflow — not a black box.
Signals are tested prospectively, with status stated honestly at every step.
Technology is designed to be adopted in real hospitals and homes.
Crely brings together expertise across clinical medicine, biomedical engineering, data science, and regulatory affairs — united by the belief that continuous, interpretable monitoring can change postoperative outcomes. Additional leadership and advisor profiles are added below as they are confirmed, and advisors are listed only with their consent.
Founder and CEO of Crely. Background in electronics engineering and senior international roles across technology and healthcare, with expertise spanning digital health, biosignal processing, and global product strategy.
Advisors are distinct from Crely employees, and are listed only with their consent. Profiles are published here once confirmed.
Started to close the gap between the last check and the next in postoperative care.
Recognised within the Asia-Pacific medtech innovation community.
Physiological mechanism supported in preclinical work.
Retrospective development across post-surgical cohorts — the basis for IRIS, CLARIS, and MERIS.
Foundational intellectual property secured for the multimodal approach.
Hospital studies with pre-specified endpoints, testing the signals prospectively.
Crely operates across the United States, Singapore, and India.
Crely Inc., incorporated in Delaware.
Asia-Pacific base.
Engineering and research.
We'd welcome a conversation with clinicians, health systems, researchers, and partners who share the goal.
Contact Crely